跳至主要内容
临床试验/NCT06353373
NCT06353373尚未招募不适用

Smart Technology Facilitated In-hospital Venous Thromboembolism Prophylaxis Based on Bundled Evidence-based Prevention Strategies: the SmaVTE-BEST Study

Navy General Hospital, Beijing0 个研究点目标入组 15,626 人开始时间: 2024年9月1日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
15,626
主要终点
In-hospital VTE

研究概览

简要总结

Venous thromboembolism (VTE) is the third leading cause of cardiovascular disease deaths globally, and its incidence is increasing over the years. Hospital-acquired VTE accounts for approximately 75% of all deaths attributed to VTE. However, only half of patients with indications for VTE prophylaxis take preventive measures, and high rates of inappropriate VTE prophylaxis prescribing contribute to the gap between VTE prophylaxis and guidelines. To further minimize the gap between clinical practice and guidelines, a range of strategies have been employed across various fields of VTE prophylaxis. One of the most effective measures is the utilization of a Clinical Decision Support System (CDSS). Smart technology-based CDSS facilitates automated evaluation of VTE risk and detection, addressing issues at both the beginning and end of the in-hospital VTE prevention process. but there is still a lack of research on how to effectively implement evidence-based VTE prophylaxis in the middle of the process.

In our hospital, routine use of DeVTEcare system (a CDSS for VTE risk assessment and integrated care) for in-hospital management of VTE has been launched since 2021. This study aims to investigate the effect of integrating bundled guideline-based VTE prevention strategies into the DeVTEcare system on in-hospital VTE prophylaxis.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Discharged patients who were ≥18 years of age at admission were included in the observation cohort. If a patient had multiple hospitalizations, information on only the longest hospitalization was included in the study.

排除标准

  • Lack of diagnostic information;
  • Length of hospitalization ≤ 24 hours;
  • Patients on anticoagulation therapy at the time of admission: e.g., those with established VTE, atrial fibrillation, acute myocardial infarction, ischemic stroke, those on continuous renal replacement therapy, extracorporeal membrane pulmonary oxygenation, hemodialysis, and mechanical valve implantation status.

结局指标

主要结局

In-hospital VTE

时间窗: During the hospitalization (assessed up to 30 days)

In-hospital VTE refers to the occurrence of a VTE in a patient who did not have a VTE on admission but developed one during the course of their hospital stay.

次要结局

  • Preventable VTE(During the hospitalization (assessed up to 30 days))
  • Major bleeding(During the hospitalization (assessed up to 30 days))
  • Non-major bleeding(During the hospitalization (assessed up to 30 days))
  • Guideline-compliant prescription of VTE prophylaxis(During the hospitalization (assessed up to 30 days))
  • Hospital-related VTE death(During the hospitalization (assessed up to 30 days))

研究者

发起方
Navy General Hospital, Beijing
申办方类型
Other
责任方
Sponsor

相似试验